bNo increased risk of thyroid cancer has been found with injectable glucagon-like peptide-1 receptor agonists/b, despite earlier safety concerns...

GLP-1 drugs like Ozempic and Mounjaro show no increased thyroid cancer risk in human data, despite lawsuits over stomach paralysis and vision loss.

GLP-1 drugs like Ozempic and Mounjaro show no increased thyroid cancer risk in human data, despite lawsuits over stomach paralysis and vision loss.

FRIDAY, March 6, 2026 -- Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently...

FRIDAY, March 6, 2026 -- Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with reduced asthma exacerbation risk among...

FRIDAY, March 13, 2026 -- For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist...

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists. Initially approved...

THURSDAY, March 5, 2026 -- Adults with overweight or obesity regain much of their lost weight after cessation of glucagon-like peptide-1 receptor...

WEDNESDAY, March 4, 2026 -- Twenty percent of potentially eligible youth are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs), with...

MONDAY, March 2, 2026 -- For people with chronic migraine (CM), taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with fewer...